Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07127874 · ClinicalTrials.gov registry record · Phase 1
A Study of PHN-012 in Patients With Advanced Solid Tumors
A Phase 1 study of Pancreatic Cancer and Advanced Solid Tumors, sponsored by Pheon Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 165
- Enrollment target
- 7
- Study locations
NCT07127874 is a Phase 1 study of Pancreatic Cancer and Advanced Solid Tumors that is actively recruiting participants, run by Pheon Therapeutics. The registered enrollment target is 165 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (58% lower). The trial reports 7 study locations across 6 states.
The verdict
NCT07127874, a Phase 1 study of Pancreatic Cancer and Advanced Solid Tumors, is actively recruiting participants, sponsored by Pheon Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 165 participants
- Enrollment target
- 7
- Study locations
Study Summary
This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-012, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.
Conditions Studied
Interventions
- DRUG PHN-012
Study Locations (7)
Texas
- PHN-012-001 Site - Houston
- PHN-012-001 Site - San Antonio
District of Columbia
- PHN-012-001 Site - Washington D.C.
Massachusetts
- PHN-012-001 Site - Boston
North Carolina
- PHN-012-001 Site - Durham
Tennessee
- PHN-012-001 Site - Nashville
Virginia
- PHN-012-001 Site - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2025-09-23 |
| Est. Completion | 2028-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07127874
The ClinicalTrials.gov registry entry for NCT07127874 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (58% lower). The listed sponsor is Pheon Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which PHN-012 is the first listed.
NCT07127874 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Texas, District of Columbia, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07127874 about?
NCT07127874 is a clinical study titled "A Study of PHN-012 in Patients With Advanced Solid Tumors". This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-012, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.
What is the current status of trial NCT07127874?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 165 participants. The study started on 2025-09-23. Estimated completion is 2028-05.
What conditions does trial NCT07127874 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Advanced Solid Tumors, Advanced Cancer, Colon Cancer, Lung Cancer (NSCLC).
What interventions are being tested in trial NCT07127874?
The interventions under investigation include: PHN-012 (DRUG).
Who is sponsoring clinical trial NCT07127874?
This trial is sponsored by Pheon Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07127874 being conducted?
This trial has 7 study locations across District of Columbia, Massachusetts, North Carolina, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
RECRUITING · Phase 1
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 1
-
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
RECRUITING · Phase 1
-
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Pancreatic Cancer
All registered trials for this condition
Advanced Solid Tumors
All registered trials for this condition
District of Columbia
All trials with a study site in District of Columbia
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.